APG101, a first-in-class, fully human protein is an inhibitor of the CD95 ligand (CD95L).
The company will use the proceeds to develop APG101, and for the production of clinical material and development of a biomarker program.
Apogenix CEO and CFO Thomas Höger said the grant, along with the grants they have been awarded over the last five years totaling more than €6m, helps to develop their lead substance APG101 for the treatment of life-threatening diseases with a high unmet medical need.
”This allows us to develop APG101 for a new, promising indication, namely MDS. We firmly believe that the therapeutic potential of APG101 goes far beyond the treatment of GBM and that we have a realistic chance to show proof-of-concept in a phase II trial planned for 2013," Höger added.
Apogenix plans to commence Phase II trial for the treatment of MDS in 2013.